Literature DB >> 23418000

Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea.

Jeffrey D Lebensburger1, Robert F Sidonio, Michael R Debaun, Monika M Safford, Thomas H Howard, Isabel C Scarinci.   

Abstract

BACKGROUND: Several sickle cell clinical trials have closed due to inability to enroll patients. To limit the early cessation of a proposed clinical trial due to low accrual rates, we sought to better understand barriers and facilitators to enrolling parents of children with sickle cell anemia (SCD) into clinical trials. PROCEDURE: Focus groups (n = 3) were conducted with parents/guardians (n = 14) who had not previously been recruited for a clinical trial and were not administering hydroxyurea to their children.
RESULTS: Three main themes related to barriers to clinical trial enrollment were identified during analysis of focus groups: general barriers to health related research (general mistrust of research studies, emotional and practical concerns), barriers to trial design (randomization), and barriers to hydroxyurea (long term unknown risks, cancer, myelosuppressive effects). Facilitators identified were need for more education, including request for peer education, and improved explanation of clinical trials or study rationale.
CONCLUSION: Engagement of parents/guardians of children with SCD in identifying barriers and facilitators to clinical trial enrollment may be critical to the development of strategies to enhance SCD trial completion.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418000      PMCID: PMC5319435          DOI: 10.1002/pbc.24486

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  17 in total

1.  The prevalence and economic impact of low-enrolling clinical studies at an academic medical center.

Authors:  Darlene R Kitterman; Steven K Cheng; David M Dilts; Eric S Orwoll
Journal:  Acad Med       Date:  2011-11       Impact factor: 6.893

2.  Development of a theory-based (PEN-3 and Health Belief Model), culturally relevant intervention on cervical cancer prevention among Latina immigrants using intervention mapping.

Authors:  Isabel C Scarinci; Lisa Bandura; Bertha Hidalgo; Andrea Cherrington
Journal:  Health Promot Pract       Date:  2011-03-21

3.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors:  Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

4.  Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study.

Authors:  Anjali S Advani; Benjamin Atkeson; Carrie L Brown; Bercedis L Peterson; Laura Fish; Jeffrey L Johnson; Jon P Gockerman; Marc Gautier
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

5.  Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial.

Authors:  Marlene H Peters-Lawrence; Margaret C Bell; Lewis L Hsu; Ifeyinwa Osunkwo; Phillip Seaman; Miren Blackwood; Edouard Guillaume; Rita Bellevue; Lakshmanan Krishnamurti; Wally R Smith; Carlton D Dampier; Caterina P Minniti
Journal:  Contemp Clin Trials       Date:  2011-12-02       Impact factor: 2.226

6.  Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).

Authors:  Lori Styles; Carrie G Wager; Richard J Labotka; Kim Smith-Whitley; Alexis A Thompson; Peter A Lane; Lillian E C McMahon; Robin Miller; Susan D Roseff; Rathi V Iyer; Lewis L Hsu; Oswaldo L Castro; Kenneth I Ataga; Onyinye Onyekwere; Maureen Okam; Rita Bellevue; Scott T Miller
Journal:  Br J Haematol       Date:  2012-03-30       Impact factor: 6.998

7.  Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study.

Authors:  Lynn Wynn; Scott Miller; Lane Faughnan; Zhaoyu Luo; Ellen Debenham; Lea Adix; Billie Fish; Tally Hustace; Tracy Kelly; Marylou Macdermott; Joan Marasciulo; Brenda Martin; Jennifer McDuffie; Mary Murphy; Betsy Rackoff; Caroline Reed; Phillip Seaman; Glenda Thomas; Winfred Wang
Journal:  Contemp Clin Trials       Date:  2010-08-24       Impact factor: 2.226

8.  Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure.

Authors:  Michael R DeBaun; Sharada A Sarnaik; Mark J Rodeghier; Caterina P Minniti; Thomas H Howard; Rathi V Iyer; Baba Inusa; Paul T Telfer; Melanie Kirby-Allen; Charles T Quinn; Françoise Bernaudin; Gladstone Airewele; Gerald M Woods; Julie Ann Panepinto; Beng Fuh; Janet K Kwiatkowski; Allison A King; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Hernan Sabio; Corina E Gonzalez; Suzanne L Saccente; Karen A Kalinyak; John J Strouse; Jason M Fixler; Mae O Gordon; J Phillip Miller; Michael J Noetzel; Rebecca N Ichord; James F Casella
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

9.  Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II.

Authors:  J M Falletta; G M Woods; J I Verter; G R Buchanan; C H Pegelow; R V Iyer; S T Miller; C T Holbrook; T R Kinney; E Vichinsky
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

10.  Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials.

Authors:  Joel B Braunstein; Noëlle S Sherber; Steven P Schulman; Eric L Ding; Neil R Powe
Journal:  Medicine (Baltimore)       Date:  2008-01       Impact factor: 1.889

View more
  18 in total

1.  Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.

Authors:  Robert S Nickel; Ifeyinwa Osunkwo; Aneesah Garrett; Jennifer Robertson; David R Archer; Daniel E L Promislow; John T Horan; Jeanne E Hendrickson; Leslie S Kean
Journal:  Br J Haematol       Date:  2015-03-05       Impact factor: 6.998

2.  Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial.

Authors:  Oluwakemi Badaki-Makun; J Paul Scott; Julie A Panepinto; T Charles Casper; Cheryl A Hillery; J Michael Dean; David C Brousseau
Journal:  Pediatr Blood Cancer       Date:  2014-01-17       Impact factor: 3.167

3.  Mistrust of Pediatric Sickle Cell Disease Clinical Trials Research.

Authors:  Evelyn M Stevens; Chavis A Patterson; Yimei B Li; Kim Smith-Whitley; Lamia P Barakat
Journal:  Am J Prev Med       Date:  2016-07       Impact factor: 5.043

4.  Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease.

Authors:  Susan E Creary; Avani C Modi; Joseph R Stanek; Deena J Chisolm; Sarah H O'Brien; Cara Nwankwo; Lori E Crosby
Journal:  J Pediatr Psychol       Date:  2019-11-01

Review 5.  Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review.

Authors:  Caren Heller; Joyce E Balls-Berry; Jill Dumbauld Nery; Patricia J Erwin; Dawn Littleton; Mimi Kim; Winston P Kuo
Journal:  Contemp Clin Trials       Date:  2014-08-15       Impact factor: 2.226

Review 6.  Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov.

Authors:  Jeffrey D Lebensburger; Lee M Hilliard; Lauren E Pair; Robert Oster; Thomas H Howard; Gary R Cutter
Journal:  Clin Trials       Date:  2015-06-17       Impact factor: 2.486

7.  Process and strategies for patient engagement and outreach in the Sickle Cell Disease (SCD) community to promote clinical trial participation.

Authors:  C Byrnes; M Botello-Harbaum; T Clemons; L Bailey; K M Valdes; V H Coleman-Cowger
Journal:  J Natl Med Assoc       Date:  2022-01-31       Impact factor: 1.798

Review 8.  Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework.

Authors:  Sherif M Badawy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

9.  Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial.

Authors:  Jane S Hankins; Mary Beth McCarville; Angela Rankine-Mullings; Marvin E Reid; Clarisse L C Lobo; Patricia G Moura; Susanna Ali; Deanne P Soares; Karen Aldred; Dennis W Jay; Banu Aygun; John Bennett; Guolian Kang; Jonathan C Goldsmith; Matthew P Smeltzer; James M Boyett; Russell E Ware
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

10.  Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists.

Authors:  Andrew R Wong; Virginia Sun; Kevin George; Jennifer Liu; Simran Padam; Brandon A Chen; Thomas George; Arya Amini; Daneng Li; Mina S Sedrak
Journal:  JCO Oncol Pract       Date:  2020-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.